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Abstract: The use of mesenchymal stromal cells (MSCs) in regenerative medicine and tissue en-
gineering is well established, given their properties of self-renewal and differentiation. However,
several studies have shown that these properties diminish with age, and understanding the pathways
involved are important to provide regenerative therapies in an ageing population. In this PRISMA
systematic review, we investigated the effects of chronological donor ageing on the senescence of
MSCs. We identified 3023 studies after searching four databases including PubMed, Web of Science,
Cochrane, and Medline. Nine studies met the inclusion and exclusion criteria and were included in
the final analyses. These studies showed an increase in the expression of p21, p53, p16, ROS, and
NF-κB with chronological age. This implies an activated DNA damage response (DDR), as well as
increased levels of stress and inflammation in the MSCs of older donors. Additionally, highlighting
the effects of an activated DDR in cells from older donors, a decrease in the expression of proliferative
markers including Ki67, MAPK pathway elements, and Wnt/β-catenin pathway elements was
observed. Furthermore, we found an increase in the levels of SA-β-galactosidase, a specific marker of
cellular senescence. Together, these findings support an association between chronological age and
MSC senescence. The precise threshold for chronological age where the reported changes become
significant is yet to be defined and should form the basis for further scientific investigations. The
outcomes of this review should direct further investigations into reversing the biological effects of
chronological age on the MSC senescence phenotype.
Keywords: mesenchymal stromal cells; senescence; ageing; biomarkers; systematic review; human
1. Introduction
Mesenchymal stromal cells (MSCs) are a heterogeneous population of stromal cells
capable of self-renewal and multi-lineage differentiation into various tissues of mesoder-
mal origin [1]. Although MSCs were originally isolated from bone marrow [2], recent
research has identified alternative sources, including adipose tissue [3], dental pulp [4], the
endometrium [5], peripheral blood [6], the periodontal ligament [7], the placenta [8], the
synovial membrane [9], and umbilical cord blood [10]. Evidence has suggested that MSCs
can be found in all vascularized tissues of the body [11]. MSCs have a high proliferative
potential, multipotency, immunomodulatory activity, and paracrine effect [12–14]. These
features, as well as the lack of ethical concerns that surround embryonic stem cells, make
MSCs a promising material for cell therapy, regenerative medicine, immune modulation,
and tissue engineering [15]. In the last decade, they have been increasingly used in clinical
practice to treat numerous traumatic and degenerative disorders [16].
Although there is no consensus on a single surface molecule to identify MSCs, the
International Society for Cellular Therapy (ISCT) proposed a minimum of three criteria
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that need to be satisfied for a cell to be considered an MSC [17]: (a) adherence to plastic
under standard culture conditions; (b) expression of CD73, CD90, and CD105, and lack
of expression of CD11b or CD14, CD34, CD45, CD19 or CD79a, and HLA-DR; (c) differ-
entiation into adipocytes, chondrocytes, and osteoblasts in vitro. Other surface markers
generally expressed by MSCs include CD10, CD13, CD29, and CD44 [18,19].
Although MSCs are present in several tissues, their numbers are low within the
aspirate. Thus, to be clinically useful, MSCs need to be expanded in vitro over several
population doublings (PDs) to obtain enough cells before implantation. The chronological
age of a donor strongly influences the quality and lifespan of MSCs [20,21]; MSCs from
aged donors perform less well than their younger counterparts because of their reduced
proliferative capacity and differentiation potential [22]. Additionally, their regenerative
potential declines after 30 years of age [23]. This is further supported by the observation
that human umbilical cord MSCs, being neonatal in origin, can grow up to passage 10
without losing multipotential capacity [24], and exhibit enhanced expression of telomerase
and pluripotency factors compared to adult bone marrow-derived MSCs [25].
While in vivo ageing refers to the chronological age of the donor, which affects the
lifespan of MSCs, in vitro ageing is the loss of MSC characteristics as they acquire a senes-
cent phenotype during expansion in culture. Irrespective of donor age, during in vitro
expansion, the proliferation rate progressively decreases until growth arrests [26–29]. This
was first proposed by Hayflick in 1965, who suggested that all primary cells cease to prolif-
erate after a certain number of cell divisions in a process known as cellular senescence [30].
Senescence negatively affects the differentiation capacities of MSCs, resulting in reduced
efficacy following transplantation [31]. Several biological markers have been proposed to
drive senescence. These include p16, p21, p53, and nuclear factor kappa B (NF-κB) [32,33].
They take part in several biochemical pathways of the cell cycle. Other markers, such as
superoxide dismutase (SOD), are found to inhibit the cell from reaching that state [34]. The
levels of the aforementioned markers differ as the MSCs undergo chronological ageing.
For MSCs to be clinically effective in an ageing population, it would be of great
significance to monitor senescence and understand the molecular basis of chronological
ageing. This systematic review aims to provide the reader with the current knowledge
about the effect of chronological ageing on MSC senescence. The molecular mechanisms
involved in the age-related decline of the therapeutic potential of MSCs will also be
discussed.
2. Results
2.1. Characteristics of Included Studies
Nine studies were included in this systematic review, as per Table 1. Sample sizes
ranged from 8 to 57, while the donors’ chronological age ranged from 6 to 92 years of age.
All studies used a system of dividing donors into age groups, and only data for patients
over 18 years of age were analysed. These data are shown in detail in Table 1. Four studies
used adipose tissue for the purposes of their experiments and three studies used bone
marrow. Pandey et al. (2011) [33] used both adipose- and bone marrow-derived MSCs,
while Ferretti et al. (2015) [35] used periosteal tissue.
2.2. Cell Surface Characterisation
In terms of cell surface characterisation, all studies analysed the cell surface markers
of the cells, with all but Ferretti et al. (2015) [35] presenting their results. Eight studies
looked at CD90, seven studies looked at CD105, and five studies looked at CD73. Although
it appears that CD90 is a universally accepted marker for the definition of MSCs, the rest
of the surface markers proposed by ISCT were not always used. Most of the included
studies showed CD34- [32,33,36–40] and CD45- [32,33,36–39] cell surface characterisation,
as per the criteria of ICST. Several surface markers not included in the ICST criteria are
repeatedly seen in the included studies as defining features of an MSC population including
CD44 [32–34,36–40], CD29 [33,37,38,40], CD146 [36,37], and CD166 [33,37,38].
Int. J. Mol. Sci. 2021, 22, 7945 3 of 15
2.3. Molecular Markers of Senescence
The markers of senescence are outlined in Table 2. Stolzing et al. (2008) [34] measured
senescence by means of flow cytometry of p21 and p53; reactive oxygen species (ROS);
nitric oxide (NO); advanced glycation end-products (AGEs), and their receptors (RAGEs);
SOD; heat shock proteins HSP27, HSP70, and HSP90; as well as by measuring the rate
of apoptosis. Wagner et al. (2009) [37] assessed the upregulation or downregulation of
various genes. Pandey et al. (2011) [33] measured NF-κB in adipose MSCs (ASCs), as
well as the proteomic, miRNA, and RNA profile. Alt et al. (2012) [36] looked at CHEK1,
p16ink4a, ATM, E2F4 transcription factor, Rb1, BRCA1, HMGA2, ATR, NFκB, TNFa,
hTERT, p53, Casp3, Casp8, Casp9, XRCC4, XRCC6, APEXZ1, Let7g, mir-27B, mir-106a,
and mir-199a. Siegel et al. (2013) [38] looked at Oct4, Nanog, Prdm14, and SOX2 as
markers of pluripotency. Choudhery et al. (2014) [39] measured the levels of p16, p21,
SA-β-galactosidase, and SOD. Ferretti et al. (2015) [35] measured Ki67, p53, NO, Bmp2,
Runx2, IL-6, OPG, RANKL, Oct4, Nanog, and Sox2. Marędziak et al. (2016) [40] measured
SA-β-galactosidase, ROS, NO, SOD, p21, p53, and the number of dead cells. Finally, Liu
et al. (2017) [32] focused on SA-β-galactosidase, mitochondrial superoxide content, ROS,
the activity of the proteasome, hTERT1, and SIRT1, as well as p16, p21, and p53.
2.4. Increased Expression of p21, p53, p16, ROS, and NF-κB with Age
p21 and p53 were assessed with flow cytometry and qRT-PCR and showed a significant
increase in expression with chronological age, with Stoltzing et al. (2008) [34] reporting
a 3-fold and 6-fold increase when comparing adult with young and aged with young
groups, respectively. Choudhery et al. (2014) [39], Marędziak et al. (2016) [40], and Liu et al.
(2017) [32] further reported an increase in the expression of p21 with age, while Ferretti et al.
(2015) [35], Marędziak et al. (2016) [40], and Liu et al. (2017) [32] reported an increase of
p53 expression levels with age. Only Alt et al. (2012) [36] reported downregulation of p53,
as measured through real-time PCR (RT-PCR). With regards to p16, Alt et al. (2012) [36],
Choudhery et al. (2014) [39], and Liu et al. (2017) [32] reported a significant increase in its
expression levels with age, as measured with quantitative RT-PCR, with Alt et al. reporting
a 22.9-fold increase.
Levels of ROS were found to significantly increase with age, as reported by three
studies [32,34,40]. Results were mixed with regards to the expression levels of NO and
SA-β-galactosidase. With respect to SA-β-galactosidase, two studies reported an increase in
its levels with age [32,39], and one reported no statistically significant differences [40]. Two
studies concluded that the levels of apoptotic regulator NF-κB increase with age, through
the use of immunohistochemistry, Western blot analysis, and RT-PCR [33,36]. Pandey et al.
(2011) investigated the changes of NF-κB through an immunohistochemical, proteomic,
and RNA profile, which showed an increase in its expression with age. Although Pandey’s
RNA profile showed an increase in the expression of non-canonical targets of NF-κB, they
also reported a decrease in the expression of canonical targets [33].
2.5. Decreased Expression of SOD with Age
Stolzing et al. (2008) [34], Choudhery et al. (2014) [39], and Marędziak et al. (2016) [40]
reported a decrease in the expression levels of SOD with age, as measured through the use
of assay kits.
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3. Discussion
While in vivo ageing refers to the chronological age of the donor, in vitro ageing is the
loss of MSC characteristics as they acquire a senescent phenotype during in vitro expansion.
For MSCs to be clinically effective in an ageing population, it would be of great significance
to monitor senescence and understand the molecular basis of chronological ageing.
The diverse nature of MSCs poses a great challenge to forming a precise characteri-
sation profile [41]. The minimal criteria to define MSCs, as proposed by the International
Society for Cellular Therapy (ISCT) [17], were an important step towards the standard-
isation of MSC models. However, it is yet unclear whether these criteria are accurate,
essential, and comprehensive. Several of the studies included in this review described
an MSC population that included some, but not all, of the minimal criteria [32–34,36–40].
The heterogeneity between MSC populations in different studies prevents the accurate
comparison of outcomes. This poses a particular challenge to the advancement of the
field. A potential solution would be to rely on functional assays, as well as surface marker
characterisation, to accurately define an MSC population. This could involve differentiation
potentials [17] and immunological characterisation [42].
3.1. Senescence
Senescence is a concept with an elusive definition. Broadly, it describes cellular
deterioration due to ageing, and a subsequent loss of growth and proliferative capacity.
Senescence is a well-documented outcome in cellular populations that undergo genotoxic
stress [43]. This is reflected in a cell’s absence of proliferation, the expression of senescence
markers, and the secretion of a senescence-associated secretory phenotype (SASP). It is
an irreversible state that protects a cell from the consequences of compromised genomic
integrity [44]. However, there is no single phenotypic definition to describe the process
of senescence, but rather a collection of phenotypes. Specifically, hallmarks of cellular
senescence include an arrest of the cell cycle, resistance to apoptosis, SA-β-gal expression,
and a SASP that is associated with growth-related oncogene (GRO), IL-8, IL-12, and
macrophage-derived chemokine (MDC) [45]. The driving cause of senescence with ageing
appears to be telomere dysfunction, as well as associated genetic and epigenetic changes,
perceived as DNA damage and activating the persistent DNA damage response (pDDR)
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mechanism [46,47]. Human MSCs have been described as exhibiting a marked resistance
to apoptosis and to default to a senescence phenotype in response to injury [31]. When
exposed to ionising radiation, p53 and p21 were seen to drive MSC cycle arrest and p16
and RB to drive senescence [48]. Similar markers were explored by some of the studies
included in this review, with SA-β-gal, inflammatory markers, and pDDR proteins being
most frequently referenced [32–34,36,39]. A reduction in the rates of proliferation, as well as
an increase in the senescence phenotype was observed in similar experiments that evaluate
the effects of in vitro ageing on MSCs [49].
3.2. Cell Cycle Arrest and Apoptosis
When assessing the effects of chronological age on MSC senescence it is essential to
evaluate evidence for cell cycle arrest and against proliferation. In the included studies,
p21 and p53 were seen to be significantly upregulated in six studies [32,34–36,39,40],
providing strong evidence for cell cycle arrest, as both molecules are central components of
the response pathway to DNA damage [50]. In addition, upregulation of p16 [32,36,39],
ATM [36], CHK1 [36], E2F4 [36], and RB [36] (illustrated in Figure 1, below) was also noted
in MSC samples from older donors, highlighting the persistent activation of the DNA
damage response pathway [51]. Although the upregulation of all mentioned markers
was rarely seen in a single study, the six studies mentioned the upregulation of at least
one marker, with the remaining three not mentioning whether they looked for a change
in their expression. Furthermore, highlighting the effects of an activated pDDR in cells
from older donors, a decrease in the expression of proliferative markers like Ki67, MAPK
pathway (illustrated in Figure 1, below) elements, and Wnt/β-catenin pathway elements
was seen in two studies [33,35]. It is unclear, however, whether the absence of proliferation
was associated with an increase in the rate of apoptosis. It is known that MSCs exhibit
resistance to apoptosis [17], and so do most senescent cells, but the evidence in the literature
was contradicting. Specifically, both mention that an increase in the rate of apoptosis [34]
and a decrease in the expression of caspases 3/8/9 [36] was seen in two different studies.
Two studies reported an increase in the expression of SA-β-galactosidase, supporting the
association between senescence and chronological age [32,40].
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products and their receptors (AGEs and RAGEs) [34] was reported, as well as a decrease
in the levels of SOD [34,39,40]. In line with an increase in markers of stress, there was
an increase in the expression of inflammatory markers amongst the older donor group.
Specifically, there was a reported increase in NF-κB [33,36], as well as TNFα [36] and
IL-6 [35]. A potential approach to subsequent studies could be the investigation of any
functional consequences on the immunological environment of MSCs from older donors,
with over-expressed inflammatory markers. Lastly, there is contradicting evidence on the
expression of potency markers in MSCs from older donors. Siegel et al. 2013 provided
evidence that there is no difference in the expression of Oct4, Sox2, or Nanog between the
two groups [38], however, Ferretti et al. (2015) suggest an increase in the expression of
Nanog and Sox2, and a decrease in Oct4, in the group of older donor MSCs [35]. Further
investigations into the effect of chronological age and MSC potency are crucial to provide a
deeper understanding of a potential mechanism of age-induced senescence in MSCs.
3.4. Strengths and Limitations
The systematic approach to constructing a research question yielded a thorough review
of the literature to identify all relevant studies. The ability to make effective comparisons
between the studies was, however, limited by the heterogeneity of the included studies
in defining the MSC population; not all studies followed the minimal defining criteria
proposed by ISCT to define their cell population. There was a large variation in the
markers explored by the different studies with most studies not investigating the effect
of chronological age on the SASP or the differentiation potential of MSC, both defined
hallmarks of senescence [45]. The included genetic studies offered a descriptive assessment
of genes that were up- and downregulated without any implications on how these genes
affect senescence pathways. Further work is needed to identify the relevant pathways
through which chronological age influences senescence in MSCs.
4. Materials and Methods
4.1. Databases
A systematic review of the existing literature was conducted, as per the guidelines of
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist [52].
The Prospero Registration Number of this systematic review is 259531. Four databases
were used for the literature search; PubMed, Cochrane, Web of Science, and Medline.
4.2. Search Terms and Inclusion and Exclusion Criteria
Our search strategy involved terms of “age” or “ageing” and “mesenchymal stem cells”
or “mesenchymal stem cell” or ”mesenchymal stromal cells” or “mesenchymal stromal
cell” and “cell surface characterisation” or “cell surface” or “differentiation potential” or
“differentiation” and “in vitro”.
Inclusion of a study required human subjects and reference to their chronological
age. Only studies referring to MSCs, as opposed to other sources of cells, were included,
while there should be a specific reference for the extraction of the MSCs from a particular
tissue source. Included studies had to include the proliferation, characterisation, and
differentiation of MSCs to allow for assessment adherence to ISCT criteria. Only studies
looking at in vitro models were included and had to be written in the English language.
Exclusion criteria included animal models and in vivo models. All case studies, editorials,
commentaries, reviews, and letters to the editor (as opposed to primary research) were
excluded. The above inclusion and exclusion criteria are an exhaustive list of limitations
for the review. The search strategy and inclusion and exclusion criteria were finalised by
AV and WK, and they resolved all potential disputes.
4.3. Data Collection and Extraction
In week 4 of January and week 1 of February 2021, DA, NC, and KK independently
conducted a search of the existing literature on the topic, using the four aforementioned
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databases and extracted 988 studies from PubMed (1996—week 4 of January 2021), 23
studies from Cochrane (1946—week 4 of January 2021), 1309 studies from Web of Science
(1900—week 4 of January 2021), and 703 studies from Medline (1946—week 1 of February
2021). A total of 966 duplicates were removed, and the rest of the studies were screened
and excluded with reasons. Then 144 full-text articles were assessed and a final list of 9
were used for the purposes of data extraction, following a 2-step screening process, as
explained in detail in Figure 2. The process was supervised by AV and WK.
The data from each included study were extracted and organised on an Excel spread-
sheet, listing the name of the primary author, publication year, brief description of the
study, number of subjects and chronological age, source of the MSCs, culture conditions,
proliferation analysis and results, MSC cell surface characterisation, protocols, and results
for chondrogenic, adipogenic, osteogenic, and other reported outcomes. AV and WK
evaluated and finalised the format of the data.




Figure 2. Overview of the identification, screening, and eligibility of studies, using the PRISMA Flow Diagram [53]. 
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4.4. Quality Assessment of Included Studies
Each of the included studies was appraised independently by DA, NC, and KK, using
the Office of Health Assessment and Translation tool (OHAT tool) [54], by answering 11
questions assessing the risk of bias of each study. A consensus with discussion was reached
regarding each study. Results of the OHAT analysis are included in the Supplementary
Materials.
5. Conclusions
Our systematic review supports an association between chronological age and MSC
senescence, with chronological ageing associated with an increased expression of the DNA
damage response proteins, markers of ageing, stress, and inflammation. We were not able to
identify a threshold of chronological age after which the phenotypic features of senescence
begin to appear. The outcomes of this review should direct further investigations into
reversing the biological effects of chronological age on the MSC senescence phenotype.
Whilst doing so, it is essential that a clear definition of MSC characterisation is maintained
across studies, ideally, aligned with the definitions suggested by the ISCT [17], and a clear
set of senescence features are investigated, like markers of cell cycle arrest, apoptosis, stress,
inflammation, differentiation, and SASP. This would help to develop a better understanding
of the pathways involved and facilitate translation to clinical practice.
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.3390/ijms22157945/s1.
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